SCHEMBL3855901

SCHEMBL3855901

CON[C@@H](Cc1cn(Cc2cccnc2)c2ccccc12)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 1/20 0.51
CNR1 P21554 1/20 0.51
CNR2 P34972 1/20 0.51
KDM4E B2RXH2 2/20 0.49
ADAM17 P78536 7/20 0.48
MMP2 P08253 1/20 0.47
MMP13 P45452 1/20 0.47
MMP14 P50281 1/20 0.47
KMT2A Q03164 1/20 0.46
CHRM1 P11229 1/20 0.46
FNTA P49354 1/20 0.45
FNTB P49356 1/20 0.45
APP P05067 1/20 0.45
SNCA P37840 1/20 0.45
LMNA P02545 2/20 0.44
ALDH1A1 P00352 1/20 0.44
MAPT P10636 1/20 0.44
MAPK1 P28482 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3855898 1.00 HTR2C (0.51) HTR2CCNR1CNR2KDM4EADAM17
SCHEMBL3855960 0.89 HTR2C (0.53) HTR2CCNR1CNR2KDM4EADAM17
SCHEMBL3855969 0.89 HTR2C (0.53) HTR2CCNR1CNR2KDM4EADAM17
SCHEMBL3852357 0.88 HTR2C (0.57) HTR2CCNR1CNR2KDM4EADAM17
SCHEMBL3852365 0.88 HTR2C (0.57) HTR2CCNR1CNR2KDM4EADAM17
SCHEMBL3848661 0.84 ADAM17 (0.63) ADAM17MMP2MMP13MMP14CHRM1
SCHEMBL3848667 0.84 ADAM17 (0.63) ADAM17MMP2MMP13MMP14CHRM1
SCHEMBL3853676 0.83 ADAM17 (0.56) ADAM17MMP2MMP13MMP14KMT2A
SCHEMBL3852584 0.83 ADAM17 (0.49) ADAM17MMP2MMP13MMP14KMT2A
SCHEMBL3852590 0.83 ADAM17 (0.49) ADAM17MMP2MMP13MMP14KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576222-B2 N-{[4-(but-2-ynyloxy)phenyl]sulfonyl}-1-(2-fluorobenzyl)-5-methoxy-2-methyltryptophan; for treatment of rheumatoid arthritis, juvenile rheumatoid arthritis, ulcerative colitis, or Crohn's disease WYETH (US) 2009-08-18 US disclosed
US-20060160884-A1 Alkynyl-containing tryptophan derivative inhibitors of tace/matrix metalloproteinase WYETH (US) 2006-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160884-A1 Alkynyl-containing tryptophan derivative inhibitors of tace/matrix metalloproteinase ADAM17, TPSAB1, ADAM10 HTR2C 627/4885CNR1 1797/4885CNR2 1776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.